Synapse - Saad Usmani

Results (105)

A pilot plant based dietary intervention in MGUS and SMM patients with elevated BMI is feasible and associated with improvements in metabolic and microbiome biomarkers of progression

Meeting Abstract

Shah, U. A.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Tran, L.; Adintori, P. A.; Burge, M.; Funkhouser, S.; Hosszu, K.; more...
Blood (2022)

Fulltext@MSK | Save

A phase 2 trial of colesevelam for lenalidomide-associated diarrhea

Meeting Abstract

Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
Blood (2022)

Fulltext@MSK | Save

Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma

Meeting Abstract

Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
Blood (2022)

Fulltext@MSK | Save

Individualized treatment-adjusted risk stratification in newly diagnosed multiple myeloma

Meeting Abstract

Maura, F.; Rajanna, A. R.; Derkach, A.; Ziccheddu, B.; Weinhold, N.; Maclachlan, K. H.; Diamond, B.; Davies, F. E.; Boyle, E.; Walker, B. A.; more...
Blood (2022)

Fulltext@MSK | Save

Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy

Meeting Abstract

Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
Blood (2022)

Fulltext@MSK | Save

Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens

Meeting Abstract

Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
Blood (2022)

Fulltext@MSK | Save

A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

Correspondence

Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets

Journal Article

Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience